Literature DB >> 16731025

Outcome prediction of enteral levodopa/carbidopa infusion in advanced Parkinson's disease.

J Westin1, D Nyholm, T Groth, M S Dougherty, P K Yerramsetty, S E Palhagen.   

Abstract

Two studies comparing intraduodenal infusion of a levodopa/carbidopa gel with oral treatments in advanced PD patients demonstrated improvement in UPDRS scores and in frequent clinical ratings on a global treatment response scale. Further analysis of data from these studies was performed to find predictive factors related to degree of improvement with infusion. Pearson's correlation coefficients between measures of improvement and baseline variables were calculated. Using data from one study, a prediction model was designed and was then evaluated using the other study's data. Correlations were found indicating that patients with more severe symptoms at baseline were most improved after infusion.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16731025     DOI: 10.1016/j.parkreldis.2006.02.006

Source DB:  PubMed          Journal:  Parkinsonism Relat Disord        ISSN: 1353-8020            Impact factor:   4.891


  4 in total

1.  Emerging issues on selection criteria of levodopa carbidopa infusion therapy: considerations on outcome of 28 consecutive patients.

Authors:  Mariachiara Sensi; F Preda; L Trevisani; E Contini; D Gragnaniello; J G Capone; E Sette; N Golfre-Andreasi; V Tugnoli; M R Tola; R Quatrale
Journal:  J Neural Transm (Vienna)       Date:  2014-01-08       Impact factor: 3.575

2.  Placement of the AbbVie PEG-J tube for the treatment of Parkinson's disease in the interventional radiology suite.

Authors:  Mark L Montgomery; Noel K Miner; Michael J Soileau; Douglas K McDonald
Journal:  Proc (Bayl Univ Med Cent)       Date:  2016-10

Review 3.  Levodopa-carbidopa enteral suspension in advanced Parkinson's disease: clinical evidence and experience.

Authors:  Johan Virhammar; Dag Nyholm
Journal:  Ther Adv Neurol Disord       Date:  2016-12-01       Impact factor: 6.570

4.  Continuous levodopa for advanced Parkinson's disease.

Authors:  Christofer Lundqvist
Journal:  Neuropsychiatr Dis Treat       Date:  2007-06       Impact factor: 2.570

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.